Wednesday, February 10, 2010
news item - court case - Charleston woman names physician, practice in medical negligence case | West Virginia Record
Note: this article does not mention what type of cancer although it references gynecologic oncology
SGO Tumor Board Discussant presentation on Ovarian Cancer Neoadjuvant Chemotherapy by Ignace B. Vergote, MD, PhD, University Hospital Leuven, Leuven Belgium
Clinical Presentation - 2/2009 (freely accessible) slide and subsequent discussion presentation on debulking procedures/neoadjuvant vs upfront surgery, maintenance therapies comparing outcomes in European/Central American/Canadian studies etc
Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse — Dr Maurie Markman et al
abstract:"Purpose: To safely assess new drugs, cancer patients in initial cohorts of phase I oncology studies receive low drug doses. Doses are successively increased until the maximum tolerated dose (MTD) is determined. Because traditional chemotherapy is often more effective near the MTD, ethical concerns have been raised about administration of low drug doses to phase I patients. However, a substantial portion of oncology trials now investigate targeted agents, which may have different dose-response relationships than cytotoxic chemotherapies.......
Note: very short abstract as below, but good points (in the absence of the full paper)
"Unlike other diseases, dose-selection for cancer therapeutics is often based on the maximum-tolerated dose in phase 1 studies involving relatively few patients. In this issue of Clinical Cancer Research, Jain and colleagues provide evidence that lower doses may be as effective as maximum-tolerated doses in the treatment of cancer patients."
"This special session for survivors will provide updates on emerging research, as well as information about patient resources. Women and their families will have the opportunity to “Ask the Expert” as well as network with other individuals sharing the same experience. Please watch this space for detailed program updates."
Editorial note (mine): colour me stupid, but at last check turquoise was not/is not teal
"With turquoise being the colour of the year, this provides us with the perfect opportunity to continue to create awareness about ovarian cancer, the deadliest of all gynecologic cancers. Celebrate our colour throughout 2010 – wear it often, tell your friends and paint your town teal!"
Abstract/full access: What physicians want to learn about sickness certification: analyses of questionnaire data from 4019 physicians
"A majority of physicians in most types of clinics/practices, not only primary care, indicated the need for more knowledge and skills in handling sickness certification cases. Increased knowledge and skills are needed in order to protect both the health and equity of patients. However, few physicians stated that they needed more skills in filling out sickness certificates, which contradicts previous findings about such documents being of poor quality and suggests that factors other than mere knowledge and skills are involved."
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study (Paroxetine/Paxil/Seroxat)
CONCLUSION: Paroxetine use during tamoxifen treatment is associated with an increased risk of death from breast cancer, supporting the hypothesis that paroxetine can reduce or abolish the benefit of tamoxifen in women with breast cancer. (trade names Seroxat, Paxil)
Blog: What Reporters Missed at the NIH Colon CA Screening State-of-the-Science Conference By: Gary Schwitzer
"....And it's difficult to understand why this didn't get news coverage. It sure sounded newsworthy to me."
"I do not want my life to be prolonged if, to a reasonable degree of medical certainty, my situation is hopeless."
"I want my life to be prolonged as long as possible within the limits of generally accepted medical standards, even if this means that I might be kept alive on machines for years."
"Check one. That's one of the places where I'm stalled on making my advance medical directive."
Augmentation of Therapeutic Efficacy in Drug-Resistance - breast and ovarian cancers - C6 (CER) + Paclitaxel
"This study describes a novel mechanism to overcome MDR through a polymer-blend nanoparticle platform that delivers a combination therapy of C6-ceramide (CER), a synthetic analog of an endogenously occurring apoptotic modulator, together with the chemotherapeutic drug paclitaxel (PTX), in a single formulation. ( PTX/CER )
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds -- Grindedal et al. 47 (2): 99 -- Journal of Medical Genetics
Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.